title: [Validating the Simpson-Angus Extrapyramidal Collateral Symptom Evaluation Scale].
abstract: OBJECTIVE
  The study was aimed at validating the Simpson-Angus scale for neuroleptic-induced extrapyramidal syndrome in Colombia, using a Spanish version of the scale.
  
  
  METHODS
  The scale was validated in four steps: translating the scale, pilot study, preliminary use for factorial analysis and analysis of validity, reliability and sensitivity to change.
  
  
  RESULTS
  Factorial structure and internal consistency were evaluated in 86 psychiatric inpatients. Test-retest and inter-rater reliability were evaluated in a 15-patient subgroup. Concurrent validity was analysed by simultaneously applying Simpson-Angus and Chouinard scales. Sensitivity to change was evaluated by comparing the scores of two different clinical points in a 20-patient subgroup. Main factor analysis revealed that the scale has a one-dimensional structure; the Glabella tap did not contribute towards total variability of the condition measured for the scale. Test-retest and inter-rater reliability values, concurrent validity and sensitivity to change were good. Correlation estimation scores were above 0.8 and accuracy levels were also good.
  
  
  CONCLUSIONS
  The Spanish version of the SA scale, adapted for this study, is suitable for assessing neuroleptic-induced extrapyramidal syndrome; it would be a useful instrument in both clinical practice and research settings in Colombia. However, an important limitation could be its lack of detecting any domain different to that of rigidity.
authors.affiliation: Departmento de Psiquiatría, Faculdad de Medicina, Universidad de Columbia. jmcalvog@unal.edu.co
authors.forename: José Manuel
authors.initials: JM
authors.lastname: Calvo-Gómez
authors.forename: Ricardo
authors.initials: R
authors.lastname: Sánchez-Pedraza
authors.forename: Luis Eduardo
authors.initials: LE
authors.lastname: Jaramillo-González
authors.forename: Carlos
authors.initials: C
authors.lastname: Tarcisio-Mantilla
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000453:epidemiology; D003105:Colombia / Q000453:epidemiology; D005260:Female; D006801:Humans; D007297:Inpatients / Q000523:psychology; D007802:Language; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000453:epidemiology; D010865:Pilot Projects; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
chemical_list: D014150:Antipsychotic Agents